Amechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

Blood

Volumn 117, Issue 8, 2011, Pages 2396-2404

  Annunziata, Christina M ^a   Hernandez, Lidia ^a   Davis, R Eric ^a   Zingone, Adriana ^a   Lamy, Laurence ^a   Lam, Lloyd T ^a   Hurt, Elaine M ^a   Shaffer, Arthur L ^a   Kuehl, W Michael ^a   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; HISTONE LYSINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE; PROTEIN V MAF; REPRESSOR PROTEIN; WHSC1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE MAF; PRIORITY JOURNAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY;

APOPTOSIS; GENE EXPRESSION REGULATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPLE MYELOMA; ONCOGENE PROTEIN V-MAF; PROTEIN KINASES; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 79952123613     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-278788     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2007;59(4):225-249.
2. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol. 2008;26(3):480-492. (Pubitemid 351171703)
3. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028. (Pubitemid 44395016)
4. Eychene A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer. 2008;8(9):683-693.
5. Hurt EM, Wiestner A, Rosenwald A, et al. Over-expression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191-199. (Pubitemid 38283804)
6. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995; 270(28):16483-16486.
7. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74(10):589-607. (Pubitemid 26343761)
8. Lunghi P, Giuliani N, Mazzera L, et al. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood. 2008;112(6):2450-2462.
9. Dai Y, Chen S, Pei XY, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood. 2008;112(6):2439-2449.
10. Breitkreutz I, Raab MS, Vallet S, et al. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007;139(1):55-63. (Pubitemid 47389922)
11. Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010;149(4):537-549.
12. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res. 2005;11(1):28-40. (Pubitemid 40075775)
13. Ngo VN, Davis RE, Lamy L, et al.Aloss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441(7089):106-110.
14. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-1874. (Pubitemid 34028664)
15. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201): 226-231. (Pubitemid 351969894)
16. Keats JJ, Maxwell CA, Taylor BJ, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood. 2005; 105(10):4060-4069. (Pubitemid 40656156)
17. Martinez-Garcia E, Popovic R, Min DJ, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117(1):211-220.
18. Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008;68(22):9375-9383.
19. Garon EB, Finn RS, Hosmer W, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010;9(7):1985-1994.
20. Pei XY, Dai Y, Tenorio S, et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood. 2007;110(6):2092-2101. (Pubitemid 47443927)
21. Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem. 1997;272(30):18586-18594. (Pubitemid 27318198)
22. Kang S, Dong S, Gu TL, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007;12(3):201-214. (Pubitemid 47333416)
23. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003;101(6):2374-2376. (Pubitemid 36302083)
24. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338. (Pubitemid 46218843)
25. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med. 2005;202(10):1363-1374. (Pubitemid 41668739)
26. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):797-816. (Pubitemid 350215385)
27. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta. 2007;(8):1773: 1248-1255. (Pubitemid 47161034)
28. Tai YT, Fulciniti M, Hideshima T, et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007;110(5):1656-1663. (Pubitemid 47443984)
29. Friday BB, Yu C, Dy GK, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 2008;68(15):6145-6153.
30. Matsui TA, Murata H, Sowa Y, et al. A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells. Oncol Rep. 2010;24(2):329-333.
31. Quinones RR. Hematopoietic engraftment and graft failure after bone marrow transplantation. Am J Pediatr Hematol Oncol. 1993;15(1):3-17. (Pubitemid 23061706)
32. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets. 2002;2(1):37-43. (Pubitemid 34627377)
33. Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis. 2006;23(5-6):291-300.